HIV Infections Clinical Trial
Official title:
Economic Outcomes of HIV/AIDS Care and Treatment in South Africa
The purpose of this study is to determine the social and economic outcomes of anti-HIV treatment in South African adults, with data collected from interviews, detailed questionnaires, and patients' medical records.
The Government of the Republic of South Africa is implementing a national program to provide
antiretroviral therapy (ART) to all eligible HIV infected South African adults. While the
medical effectiveness of ART in suppressing viral replication is well established, little is
known about the economic effectiveness of treatment. In particular, it is not known if
treatment will offset the impact of HIV/AIDS on labor productivity, household stability,
quality of life, and other aspects of social and economic development. The purpose of this
study is to estimate the impact of ART on the productivity, economic welfare, and quality of
life of adult HIV infected patients in South Africa. The study will investigate:
- the degree of functional impairment among patients seeking care for HIV/AIDS,
- the impact of treatment on the ability of patients to perform normal daily activities
and attend work,
- the full economic costs to patients of obtaining treatment,
- the impact of treatment on sources of household income,
- social and economic correlates of adherence to therapy, and
- the cost of delivering ART to different types of patients in diverse settings.
The study will last 4 years and will comprise a one-year cross-sectional analysis and a
three-year longitudinal analysis. Data will be collected from questionnaires administered
during patients' routine visits to public and non-governmental organization-based HIV
clinics in South Africa. In accordance with current South African national treatment
guidelines, patients who have started ART will visit a clinic every 3 months during the
longitudinal analysis for a total of 12 visits; patients not yet on ART will visit a clinic
every 6 months for a total of 6 visits.
Questionnaire responses will be matched to indicators of disease progression and treatment
history drawn from patients' medical records. The initial one-year analysis will compare
outcomes for groups of patients stratified by disease stage and treatment duration.
Longitudinal analysis will compare outcomes before and after the initiation of ART; each
participant's responses and medical outcomes will be compared with his or her own previous
results and with those of other participants at a similar stage of disease progression or
treatment duration. This study will generate information needed to sustain large-scale
treatment interventions, improve the focus and management of treatment delivery programs,
and provide a better understanding of barriers to treatment adherence among HIV infected
South African patients.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |